Maisha Maliha

Maisha Maliha


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
ANAhmad Moayad Naser
Ahmad Moayad Naser
RVRhea Vyas
Rhea Vyas
AMAhmed Morgan
Ahmed Morgan
AKAbdul Mukhtadir Kalaiger
Abdul Mukhtadir Kalaiger
AKAmrin Kharawala
Amrin Kharawala
RFRobert T. Faillace
Robert T. Faillace
Pulmonary embolism (PE) remains a critical condition with significant mortality and morbidity, necessitating timely detection and intervention to improve patient outcomes. This review examines the evolving role of artificial intelligence (AI) in PE management. Two primary AI-driven models that are currently being explored are deep convolutional neural networks (DCNNs) for enhanced image-based detection and natural language processing (NLP) for improved risk stratification using electronic health records. A major advancement in this field was the FDA approval of the Aidoc© AI model, which has demonstrated high specificity and negative predictive value in PE diagnosis from imaging scans. Additionally, AI is being explored for optimizing anticoagulation strategies and predicting PE recurrence risk. While further large-scale studies are needed to fully establish AI’s role in clinical practice, its integration holds significant potential to enhance diagnostic accuracy and overall patient management.

6 August 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
VMVishakha Modak
Vishakha Modak
VSVikyath Satish
Vikyath Satish
MMMaisha Maliha
Maisha Maliha
SKSriram Sunil Kumar
Sriram Sunil Kumar
PCPanagiota Christia
Panagiota Christia
Myocardial viability assessment plays a critical role in the clinical management of patients with ischemic heart disease, particularly in guiding revascularization decisions. Various non-invasive imaging modalities have been developed and refined to evaluate viable myocardium, each offering unique insights into myocardial perfusion, metabolism, and contractile function. This review examines the comparative strengths and limitations of key imaging techniques. Understanding the pathophysiological basis and diagnostic capabilities of these modalities enables clinicians to tailor viability assessments to individual patient profiles, ultimately enhancing decision-making and optimizing outcomes in ischemic cardiomyopathy.

11 August 2026 in Diabetology
Verified
Journal Article
Open access
PDF file
RDRaptis Dimitrios
Raptis Dimitrios
NNNatalia Nazarenko
Natalia Nazarenko
Raksheeth AgarwalRaksheeth Agarwal
Raksheeth Agarwal
MSMandar Kalpesh Shah
Mandar Kalpesh Shah
YGYiqi Gao
Yiqi Gao
NFNaomi Friedman
Naomi Friedman
Background/Objectives: People living with HIV (PLWH) who undergo prolonged antiretroviral therapy (ART) may experience weight gain as a potential side effect. Many of these individuals are prescribed glucagon-like peptide 1 (GLP-1) receptor agonists (RAs), or dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) RAs, which are known for their weight-reducing effects and positive impact on metabolic health. However, studies investigating their effects on PLWH are limited. Methods: We conducted a retrospective study at a public hospital in the Bronx, New York, among PLWH with obesity and/or type 2 diabetes mellitus (T2DM) prescribed GLP-1 or dual GLP-1/GIP RAs between August 2020 to March 2024. We collected baseline measurements of weight, body mass index (BMI), glycated hemoglobin (HbA1c), and lipid panel, before and after initiation of treatment, to assess the potential metabolic changes associated with the therapy. Logistic regression was used to analyze the factors associated with reductions in HbA1c and weight. Results: A total of 202 patients were included in the final study, with a mean duration of 24.2 months of GLP-1 or GLP-1/GIP RA therapy. A mean HbA1c reduction of 1.0% (p < 0.001), a mean BMI reduction of 0.7 kg/m2 (p < 0.001), and an average mean weight loss of 3.55% were observed. In the univariate analysis, the duration of GLP-1 or GLP-1/GIP RA use was the only factor independently associated with HbA1c reduction greater than 1% (p = 0.027). However, no correlation was found between the duration of their use and the percentage of weight loss (p = 0.126). Insulin use was associated with less weight loss (p = 0.048), while younger age was associated with greater weight loss (p = 0.048). No significant differences in weight loss were observed when the population was stratified by sex, race, comorbidities, type of GLP-1 RA therapy, or other antidiabetic or ART regimens. Conclusions: Use of GLP-1 RAs among PLWH with obesity and/or T2DM is associated with reductions in HbA1c and BMI. In this diverse cohort, which predominantly consists of Black and Hispanic individuals, longer duration of treatment was associated with reductions in HbA1c greater than 1%. These findings encourage GLP-1 RA-related treatment for PLWH with obesity and/or T2DM. Further prospective studies with larger cohorts are needed to confirm these benefits and better define their effects on long-term metabolic health.